Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma.

Palacio S, Hosein PJ, Reis I, Akunyili II, Ernani V, Pollack T, Macintyre J, Restrepo MH, Merchan JR, Rocha Lima CM.

J Gastrointest Oncol. 2018 Feb;9(1):135-139. doi: 10.21037/jgo.2017.10.12.

2.

Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.

Jing Y, Chavez V, Ban Y, Acquavella N, El-Ashry D, Pronin A, Chen X, Merchan JR.

Mol Cancer Res. 2017 Oct;15(10):1410-1420. doi: 10.1158/1541-7786.MCR-17-0016. Epub 2017 Jul 5.

3.

Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma.

Narayanan G, Hosein PJ, Beulaygue IC, Froud T, Scheffer HJ, Venkat SR, Echenique AM, Hevert EC, Livingstone AS, Rocha-Lima CM, Merchan JR, Levi JU, Yrizarry JM, Lencioni R.

J Vasc Interv Radiol. 2017 Mar;28(3):342-348. doi: 10.1016/j.jvir.2016.10.023. Epub 2016 Dec 16.

PMID:
27993507
4.

A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.

Montero AJ, Kwon D, Flores A, Kovacs K, Trent JC, Benedetto P, Rocha-Lima C, Merchan JR.

Clin Cancer Res. 2016 Jul 1;22(13):3209-17. doi: 10.1158/1078-0432.CCR-15-2184. Epub 2016 Feb 10.

5.

2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation.

Kovács K, Decatur C, Toro M, Pham DG, Liu H, Jing Y, Murray TG, Lampidis TJ, Merchan JR.

Mol Cancer Ther. 2016 Feb;15(2):264-75. doi: 10.1158/1535-7163.MCT-14-0315. Epub 2015 Dec 4.

6.

Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.

Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CW, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Lima CM, Hosein PJ.

Pancreatology. 2015 Nov-Dec;15(6):667-73. doi: 10.1016/j.pan.2015.08.010. Epub 2015 Sep 12.

PMID:
26412296
7.

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.

Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C.

Cancer Chemother Pharmacol. 2015 Mar;75(3):485-93. doi: 10.1007/s00280-014-2668-5. Epub 2015 Jan 3.

8.

Targeting tumor vasculature through oncolytic virotherapy: recent advances.

Toro Bejarano M, Merchan JR.

Oncolytic Virother. 2015 Nov 11;4:169-81. doi: 10.2147/OV.S66045. eCollection 2015. Review.

9.

In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.

Jing Y, Bejarano MT, Zaias J, Merchan JR.

Breast Cancer Res Treat. 2015 Jan;149(1):99-108. doi: 10.1007/s10549-014-3236-8. Epub 2014 Dec 18.

10.

In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.

Jing Y, Zaias J, Duncan R, Russell SJ, Merchan JR.

Gene Ther. 2014 Mar;21(3):289-97. doi: 10.1038/gt.2013.84. Epub 2014 Jan 16.

11.

Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.

Palacio S, Loaiza-Bonilla A, Kittaneh M, Kyriakopoulos C, Ochoa RE, Escobar M, Arango B, Restrepo MH, Merchan JR, Rocha Lima CM, Hosein PJ.

Anticancer Res. 2014 Jan;34(1):301-6.

PMID:
24403478
12.

Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.

Kurisetty VV, Heiber J, Myers R, Pereira GS, Goodwin JW, Federspiel MJ, Russell SJ, Peng KW, Barber G, Merchan JR.

Head Neck. 2014 Nov;36(11):1619-27. doi: 10.1002/hed.23502. Epub 2014 Feb 1.

13.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK.

N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.

14.

Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy.

Xi H, Barredo JC, Merchan JR, Lampidis TJ.

Biochem Pharmacol. 2013 May 15;85(10):1463-77. doi: 10.1016/j.bcp.2013.02.037. Epub 2013 Mar 13.

PMID:
23500541
15.

Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects.

Jing Y, Kovacs K, Kurisetty V, Jiang Z, Tsinoremas N, Merchan JR.

Mol Cancer Res. 2012 Oct;10(10):1271-81. doi: 10.1158/1541-7786.MCR-12-0145. Epub 2012 Aug 21.

16.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM.

BMC Cancer. 2012 May 29;12:199. doi: 10.1186/1471-2407-12-199.

17.

A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.

Hosein PJ, de Lima Lopes G Jr, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM.

Am J Clin Oncol. 2013 Apr;36(2):151-6. doi: 10.1097/COC.0b013e3182436e8c.

PMID:
22307213
18.

The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation.

Isham CR, Tibodeau JD, Bossou AR, Merchan JR, Bible KC.

Br J Cancer. 2012 Jan 17;106(2):314-23. doi: 10.1038/bjc.2011.522. Epub 2011 Dec 20.

19.

Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.

Wang X, Li G, Wang A, Zhang Z, Merchan JR, Halmos B.

Mol Carcinog. 2013 Mar;52(3):218-28. doi: 10.1002/mc.21846. Epub 2011 Nov 28.

20.

Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.

Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM.

Am J Clin Oncol. 2012 Oct;35(5):446-50.

PMID:
21552097
21.

Antiangiogenic activity of 2-deoxy-D-glucose.

Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ.

PLoS One. 2010 Oct 27;5(10):e13699. doi: 10.1371/journal.pone.0013699.

22.

Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.

Jing Y, Tong C, Zhang J, Nakamura T, Iankov I, Russell SJ, Merchan JR.

Cancer Res. 2009 Feb 15;69(4):1459-68. doi: 10.1158/0008-5472.CAN-08-2628. Epub 2009 Feb 10.

23.

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.

JAMA. 2006 Jun 7;295(21):2516-24.

PMID:
16757724
24.

Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.

Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, Karumanchi SA, Russell SJ, Sukhatme VP.

J Natl Cancer Inst. 2006 Jun 7;98(11):756-64.

PMID:
16757700
25.

A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML.

J Urol. 2005 Nov;174(5):1759-63; discussion 1763.

PMID:
16217278
26.

Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression.

Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ.

Cancer Res. 2005 Jun 15;65(12):5292-300.

27.

Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.

Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP.

Int J Cancer. 2005 Jan 20;113(3):490-8.

28.

Antiangiogenic property of human thrombin.

Chan B, Merchan JR, Kale S, Sukhatme VP.

Microvasc Res. 2003 Jul;66(1):1-14. Review.

PMID:
12826069
29.

In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril.

Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP.

J Natl Cancer Inst. 2003 Mar 5;95(5):388-99.

PMID:
12618504

Supplemental Content

Loading ...
Support Center